Viatris Inc. VTRS
20.87 USD -0.19 (-0.90%)
Nov 12, 2026, 2:28 PM EST
20.87 Day range 21.20
10.19 52-week range 21.06
- YTD
- +67.63%
- 1 year
- +89.55%
News
prnewswire.com Viatris Named to Fortune's World's Best Workplaces™ List for Second Consecutive Year PITTSBURGH, Nov. 12, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Fortune's World's Best Workplaces™ list for the second…
prnewswire.com Viatris to Participate in Upcoming Investor Conferences PITTSBURGH, Nov. 11, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in fireside chats at three upcoming healthcare…
zacks.com VTRS or DHR: Which Is the Better Value Stock Right Now? Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
zacks.com Viatris Inc. (VTRS) Hit a 52 Week High, Can the Run Continue? Viatris (VTRS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
zacks.com Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
businesswire.com Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
zacks.com Here's What Key Metrics Tell Us About Viatris (VTRS) Q3 Earnings The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street…
seekingalpha.com Viatris Inc. (VTRS) Q3 2026 Earnings Call Transcript Viatris Inc. (VTRS) Q3 2026 Earnings Call Transcript
zacks.com Viatris Q3 Earnings Beat on Stronger Margins, Revenues Fall Y/Y VTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.
benzinga.com Viatris Q3 2026 Earnings Call Transcript Viatris (NASDAQ:VTRS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Viatris (VTRS) Q3 Earnings Beat Estimates Viatris (VTRS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.67 per share a year ago.
benzinga.com Viatris Raises FY2026 Adj EPS Guidance from $2.45-$2.49 to $2.56-$2.63 vs $2.51 Est; Narrows FY2026 Sales Guidance from $14.550B-$14.950B to $14.700B-$14.900B vs $14.788B Est Viatris (NASDAQ:VTRS) raises FY2026 Adj EPS guidance from $2.45-$2.49 to $2.56-$2.63 vs $2.51 analyst estimate. Narrows FY2026 sales outlook from $14.550 billion-$14.950 billion to $14.700…
prnewswire.com Viatris Reports Third-Quarter 2026 Financial Results Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in…
benzinga.com Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr Viatris Inc. ("Viatris") (NASDAQ:VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to
benzinga.com Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $14 Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $13 to $14.
benzinga.com JP Morgan Maintains Neutral on Viatris, Raises Price Target to $20 JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $18 to $20.
benzinga.com Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia In Adults Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the…
benzinga.com Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.
benzinga.com Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand its pain treatment portfolio.
benzinga.com UBS Maintains Buy on Viatris, Raises Price Target to $26 UBS analyst Ashwani Verma maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $23 to $26.- benzinga.com Oppenheimer Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $25 Oppenheimer analyst Les Sulewski initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $25.
benzinga.com Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields Analysts review high-yield healthcare stocks CVS, Viatris and Medtronic, citing ratings, price targets, dividend yields and recent company news.
benzinga.com Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $13 Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $12 to $13.
benzinga.com Viatris Secures Japan Approval For WAKIX In Treating Excessive Daytime Sleepiness Linked To Sleep Apnea And Narcolepsy Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in JapanPITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare…- benzinga.com Leerink Partners Initiates Coverage On Viatris with Outperform Rating, Announces Price Target of $20 Leerink Partners analyst Daniel Clark initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $20.
benzinga.com Argus Research Maintains Buy on Viatris, Raises Price Target to $20 Argus Research analyst Jasper Hellweg maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $15 to $20.
benzinga.com Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter earnings and revenue beat estimates.
benzinga.com Viatris Q2 Adj. EPS $0.69 Beats $0.60 Estimate, Sales $3.756B Beat $3.675B Estimate Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.60 by 15 percent. This is a 11.29 percent increase over earnings of $0.62 per…- benzinga.com Viatris Raises FY2026 Adj EPS Guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 Est; Raises FY2026 Sales Guidance from $14.450B-$14.950B to $14.550B-$14.950B vs $14.783B Est Viatris (NASDAQ:VTRS) raises FY2026 Adj EPS guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 analyst estimate. Raises FY2026 sales outlook from $14.450 billion-$14.950 billion to $14.550…
benzinga.com Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields Investors turn to dividend-yielding stocks during market turbulence. Benzinga's Analyst Stock Ratings page provides latest analyst takes on top stocks, sorted by accuracy. Ratings for three…
benzinga.com Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst ratings for high-yielding stocks, including accuracy rates.- benzinga.com Viatris’ VR‑205 Phase 3 Trial in Japan Met Primary and Key Secondary Endpoints; Safety Profile Aligned With Global Studies, NDA Filing Planned by End‑2026 VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well ToleratedVR-205 Efficacy and Safety Profile in Japanese Patients Was Consistent with the Profile Observed in Global Studies…
- benzinga.com Viatris' New Drug Application For Moderate-To-Severe Acute Pain Treatment Receives FDA's Acceptance For Review Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02…
benzinga.com RFK Jr. Wants Fewer Americans On Antidepressants — Here's Why The Debate Is Exploding U.S. officials discussed possible SSRI restrictions as RFK Jr. unveiled a broader push to reduce antidepressant use.- benzinga.com JP Morgan Maintains Neutral on Viatris, Raises Price Target to $18 JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $17 to $18.
- benzinga.com Truist Securities Maintains Buy on Viatris, Raises Price Target to $20 Truist Securities analyst Srikripa Devarakonda maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $18 to $20.
- benzinga.com 'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive Health officials explored restricting specific antidepressants among SSRI drugs-sources
- benzinga.com Viatris Affirms FY2026 Adj EPS Guidance of $2.33-$2.47 vs $2.44 Est; Affirms FY2026 Sales Guidance of $14.450B-$14.950B vs $14.638B Est Viatris (NASDAQ:VTRS) affirms FY2026 Adj EPS guidance from $2.33-$2.47 to $2.33-$2.47 vs $2.44 analyst estimate. Affirms FY2026 sales outlook from $14.450 billion-$14.950 billion to $14.450…
- benzinga.com Viatris Q1 Adj. EPS $0.59 Beats $0.50 Estimate, Sales $3.510B Beat $3.357B Estimate Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.50 by 18 percent. This is a 18 percent increase over earnings of $0.50 per share…
- benzinga.com Viatris Appoints Chief Accounting Officer Paul Campbell As Interim CFO, Effective May 8, Succeeding Theodora Mistras Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "Doretta" Mistras, Chief Financial Officer, will depart the Company for a new professional opportunity.Viatris…
- benzinga.com FDA Takes Step Forward on Testosterone Therapy for Men https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
benzinga.com Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields Investors turn to high-yielding dividend stocks in turbulent markets. Benzinga readers can check analyst ratings for top health care stocks. MDT, ABBV, VTRS are discussed.
benzinga.com Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields Investors turn to dividend-yielding stocks in turbulent markets. Benzinga readers can check analyst takes on stocks at Analyst Stock Ratings page.- benzinga.com Barclays Maintains Overweight on Viatris, Raises Price Target to $17 Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the price target from $15 to $17.
- benzinga.com GoodRx Partners With Viatris To Offer Major Brand Medications At A Discount Collaboration expands access to trusted therapies with discounted cash prices for leading brands including Lipitor®, Celebrex®, Viagra®, and Norvasc®GoodRx (NASDAQ:GDRX), the leading platform for
- benzinga.com Viatris Sees FY2026 Adj EPS $2.33-$2.47 vs $2.49 Est; Sees Sales $14.450B-$14.950B vs $14.351B Est Viatris (NASDAQ:VTRS) is looking for FY2026 Adj EPS of $2.33-$2.47 vs $2.49 analyst estimate. sees sales of $14.450 billion-$14.950 billion vs $14.351 billion analyst estimate.
benzinga.com Insights into Viatris Q4 Earnings - benzinga.com Viatris Q4 Adj. EPS $0.57 Beats $0.53 Estimate, Sales $3.690B Beat $3.532B Estimate Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 6.94 percent. This is a 5.56 percent increase over earnings of $0.54 per…
benzinga.com Earnings Scheduled For February 26, 2026 - benzinga.com Viatris Says FDA Accepts For Review sNDA For MR-141 For Treatment Of Presbyopia; FDA PDUFA Goal Date Set For October 17 FDA PDUFA Goal Date Set for October 17, 2026PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug…